MTIC
REGN icon

Missouri Trust & Investment Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Missouri Trust & Investment Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10
Closed -$7.72K – 419
2025
Q4 		$7.72K Sell
10
-4
-29% -$2.72K ﹤0.01% 336
2025
Q3 		$7.87K Hold
14
– – ﹤0.01% 348
2025
Q2 		$7.35K Buy
+14
New +$7.81K ﹤0.01% 343

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Missouri Trust & Investment Company's REGN Position: Q1 2026 in Review

Missouri Trust & Investment Company sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 10 shares — an estimated $7.72K sold.

Missouri Trust & Investment Company first reported a position in REGN in Q2 2025 and held it in 3 quarters. The position peaked at $7.87K in Q3 2025. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Missouri Trust & Investment Company reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Missouri Trust & Investment Company sold 10 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $7.72K.
  • Missouri Trust & Investment Company first reported a position in Regeneron Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Missouri Trust & Investment Company's Regeneron Pharmaceuticals position peaked at $7.87K in Q3 2025.
  • 1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Missouri Trust & Investment Company's 13F filing for Q1 2026, filed 14 May 2026.